Clinical Trial Update: A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating rituximab in combination with prednisone as initial therapy for chronic graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• PREDNISONE (Prednisone)
• Rituximab (rituximab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Graft Versus Host Disease | Phase 2 | Status: TERMINATED